Inspirna Announces Phase 1b RGX-202 Clinical Trial Data Selected for Poster Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2022 10:00 AM Eastern Daylight Time NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, announced today that it will present a poster at the 2022 American Society of Clinical Oncology
RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial
Data from Phase 1 Trial of RGX-202 Presented at 2020 ASCO Virtual Scientific Program New York, NY - May 29, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is
Rgenix Treats First Patient in Phase 1 Trial of RGX-202
NEW YORK – Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, today announced it has treated the first patient in a Phase 1 a/b study of RGX-202, an oral small molecule being developed for the